Search research articles
Contact Us
Filters
Showing results (41-50 of 77) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
March 23, 2016
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
Joaquin Mateo, David Olmos, Herlinde Dumez, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Molecular Cancer Therapeutics
|
May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer
Craig P Carden, Adam Stewart, Parames Thavasu, et al.
Molecular Cancer Therapeutics
|
June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D Baird, Jos Kitzen, Paul A Clarke, et al.
Thrombosis Research
|
December 15, 2015
Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases
Owen Mortimer Heath, Heleen J van Beekhuizen, Vivek Nama, et al.
Cancer Research
|
March 17, 2006
10th Biennial Helene Harris Memorial Trust meeting
Frances R Balkwill, Alan Ashworth, Robert C Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 77) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
March 23, 2016
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
Joaquin Mateo, David Olmos, Herlinde Dumez, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Molecular Cancer Therapeutics
|
May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer
Craig P Carden, Adam Stewart, Parames Thavasu, et al.
Molecular Cancer Therapeutics
|
June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D Baird, Jos Kitzen, Paul A Clarke, et al.
Thrombosis Research
|
December 15, 2015
Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases
Owen Mortimer Heath, Heleen J van Beekhuizen, Vivek Nama, et al.
Cancer Research
|
March 17, 2006
10th Biennial Helene Harris Memorial Trust meeting
Frances R Balkwill, Alan Ashworth, Robert C Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Page
of 8